DNM2 and Familial prostate cancer: A benefit a DNM2 inhibition to reduce cell proliferation and/or induce apoptosis was confirmed in a wide range of cancer cells including cervical epithelial cancer cells [80], prostate cancer cells [36, 42], non-small-cell lung cancer cells [81], glioblastoma cells [82], chronic myeloid leukemia cells [32], B- and T-ALL cells [31] and hepatocellular carcinoma cells [83].